NEKTAR THERAPEUTICS 8-K

What Happened
Nektar Therapeutics (NKTR) announced its financial results for the quarter ended March 31, 2026 by issuing a press release on May 7, 2026. The company furnished that press release as Exhibit 99.1 to an SEC Form 8-K under Item 2.02 (Results of Operations and Financial Condition).

Key Details

• Date filed: May 7, 2026; quarter covered: quarter ended March 31, 2026.
• Press release furnished as Exhibit 99.1 titled “Nektar Therapeutics Reports First Quarter 2026 Results.”
• The 8-K states the information is being furnished (not “filed”) and therefore is not subject to Section 18 liability or to incorporation by reference into other SEC filings.
• Company: Nektar Therapeutics, a Delaware corporation; ticker NKTR.

Why It Matters
This filing signals that Nektar has released its Q1 2026 earnings and related financial information. Retail investors should read the Exhibit 99.1 press release for specific metrics (revenue, earnings/loss, cash position, and operational updates) because the 8-K itself does not include the financial details. The “furnished, not filed” designation limits certain legal liabilities and means the release may not be incorporated into future filings.